2012
DOI: 10.1055/s-0032-1311529
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: The median survival benefit of 9 months is evident but (probably still) not significant. The more aggressive protocol 2 shows a significant better downstaging effect concerning N- and UICC-stage if R0-resection can be achieved. Insofar dose does matter!

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
(11 reference statements)
0
1
0
Order By: Relevance
“…Concerning neoadjuvant chemotherapy, most trials administered three cycles [ 5 8 ]. Recently, Steger et al [ 16 ] compared two different neoadjuvant protocols in a single center retrospective study and concluded that the more aggressive protocol showed a better downstaging effect but survival difference did not reach significance. A two cycle strategy has been evaluated by a French group comparing mitomycin/ ifosfamid/ cisplatin with surgery alone [ 2 ].…”
Section: Discussionmentioning
confidence: 99%
“…Concerning neoadjuvant chemotherapy, most trials administered three cycles [ 5 8 ]. Recently, Steger et al [ 16 ] compared two different neoadjuvant protocols in a single center retrospective study and concluded that the more aggressive protocol showed a better downstaging effect but survival difference did not reach significance. A two cycle strategy has been evaluated by a French group comparing mitomycin/ ifosfamid/ cisplatin with surgery alone [ 2 ].…”
Section: Discussionmentioning
confidence: 99%